Collecting blood samples from healthy volunteers for immune research
Official title: Blood Sampling of Healthy Volunteers for Immunological Research
Run by The Netherlands Cancer Institute · NCT03819829 · Data updated 2026-11-12
This study is collecting blood samples from healthy volunteers to see how their immune cells compare to those of people with advanced cancer.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 36 Years and up |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | The Netherlands Cancer Institute Academic / other |
| Locations | 1 site (Amsterdam) |
| Status | Recruiting |
| Started | February 5, 2019 |
| Main results expected | December 2, 2026 |
| Study ends | December 2, 2027 |
| Registry record updated | March 23, 2023 |
| Trial ID | NCT03819829 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are healthy volunteers aged over 35 with no history of cancer.
✕Probably not a fit
Patients with a history of cancer or those currently using systemic immunosuppressive medications may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to gather blood samples from healthy volunteers to analyze and characterize immune cells. Participants will donate five tubes of blood, which will be processed within 24 hours for comprehensive immune phenotyping. The goal is to establish a comparison between the immune profiles of healthy individuals and those of advanced cancer patients, using age-matched controls without a history of cancer or immunosuppressive medication.
Why it matters
Potential benefit: If successful, this research could enhance our understanding of immune responses in healthy individuals, aiding in the development of better treatments for cancer.
How similar studies have gone: Other studies have successfully utilized similar approaches to characterize immune responses, making this a well-supported methodology.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age above 35 years * Written informed consent * No history of cancer * No use of systemic immunosuppressive medication (eg. corticosteroids). Local use of corticosteroids (eg. topical or inhalation) is allowed. Exclusion Criteria: * Fever 14 days before blood withdrawal * Donated blood for the same program within the last 2 years * Pregnancy
Where it's running
-
Nki-Avl
Amsterdam, Netherlands Recruiting
Study contacts
- Principal investigator: M Kok, MD — The Netherlands Cancer Institute
- Study coordinator: M Kok, MD
- Email: m.kok@nki.nl
- Phone: 3120512
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Omitting re-excision after complete primary melanoma excision
This trial tests whether people with pT1b–pT4b cutaneous melanoma whose tumors were completely removed can safely skip the usual re-excision surgery.
-
Living long-term with advanced GIST on tyrosine kinase inhibitors
This observational project will collect medical records and patient questionnaires to see how long-term tyrosine kinase inhibitor treatment affects quality of life and survivorship for adults with advanced or metastatic GIST who have taken TKIs for at least two years.
-
Ga68-PSMA PET/CT to tell radiation damage from tumor growth in brain metastases
This project will test whether a Ga68-PSMA PET/CT scan can tell radiation necrosis apart from tumor regrowth in adults with brain metastases from lung cancer, melanoma, or breast cancer.
-
Combining olaparib with cisplatin HIPEC during interval cytoreductive surgery for ovarian cancer
This study will test whether giving the PARP inhibitor olaparib around interval cytoreductive surgery with heated intraperitoneal cisplatin (HIPEC) is safe and feasible for adults with advanced high‑grade serous ovarian or fallopian tube cancer who responded to neoadjuvant chemotherapy.
-
Whole-body HER2 PET/CT to see how 89Zr-trastuzumab accumulates in HER2-positive or HER2-mutated advanced NSCLC
This study tests whether 89Zr-trastuzumab PET/CT can show how much tracer builds up in tumors of adults with HER2-positive or HER2-mutated advanced NSCLC.
-
Two-fraction MR-guided prostate radiation with lower dose to healthy prostate and a boost to MRI-visible tumor
This will test whether giving two MRI-guided radiation sessions that lower dose to normal prostate tissue but keep a high dose to MRI-visible tumors reduces urinary and bowel side effects in men with low- or favorable-intermediate risk prostate cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.